FINNENCE ▪ THE WIRE FILE
THE WIRE · № 84046
News▼ Bearish
Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors
KINDNews
DIRECTION▼ Bearish
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
An at-the-market private placement dilutes existing holders and signals financing need.
Small biotech raises capital at market, dilutive
CATALYST TO WATCH
Use of proceeds and trial updates
MAIN RISK
Further dilution if cash burn continues
FULL DISPATCH
LEXINGTON, Mass., Oct. 16, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS) ("Curis" or the "Company"), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it has entered into...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
CONTEXTHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Centene Corporation Demonstrates Commitment to CHOICE Arrangements through Benefit Programs in Indiana, Ohio and Oklahoma2026-10-16 12:00 UTC
Centene Corporation Demonstrates Commitment to CHOICE Arrangements through Benefit Programs in Indiana, Ohio and Oklahoma2026-10-16 12:00 UTC
→CORRELATIONshares Healthcare
Nabsys Launches RepX™ for Repeat Expansion Analysis Ahead of ASHG 20262026-10-16 12:00 UTC
Nabsys Launches RepX™ for Repeat Expansion Analysis Ahead of ASHG 20262026-10-16 12:00 UTC
→CORRELATIONshares Healthcare
Antihypertensive Drugs Market to Reach USD 30.92 Billion by 20352026-10-16 12:24 UTC
Antihypertensive Drugs Market to Reach USD 30.92 Billion by 20352026-10-16 12:24 UTC
→CORRELATIONshares Healthcare
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia2026-10-16 12:30 UTC
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia2026-10-16 12:30 UTC
→CORRELATIONshares Healthcare
Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models2026-10-16 12:30 UTC
Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models2026-10-16 12:30 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.